21.06.2021 • NewsAGCBioNTech

AGC Biologics Partners with Pfizer-BioNTech

AGC Biologics has agreed to supply plasmid DNA (pDNA) to Pfizer/BioNTech for their RNA-based Covid-19 vaccine. The biopharma CDMO based in Heidelberg, Germany, will manufacture the vaccine ingredient at its Heidelberg facility.

AGC Biologics has more than 20 years of experience delivering a wide range of microbial programs to biopharma customers. The German site is its center of excellence for pDNA production and part of the company’s end-to-end cell and gene therapy offering.

The CDMO’s network spans the US, Europe and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Milan, Italy; and Chiba, Japan in addition to Heidelberg. In March, the company announced expansion plans for Milan.

AGC Biologics, headquartered in Seattly, has been formed by integration of Asahi Glass Company (AGC) Bioscience, CMC Biologics, Biomeva and Molecular Medicine. Currently employing more than 1,700 people worldwide, AGC Biologics specializes in development and manufacture of mammalian and microbial-based therapeutic proteins, viral vectors and genetically engineered cells in addition to pDNA.

Author: Dede Williams, Freelance Journalist

AGC Biologics, a biopharma CDMO based in Heidelberg, Germany, has agreed to...
AGC Biologics, a biopharma CDMO based in Heidelberg, Germany, has agreed to supply Plasmid DNA (pDNA) to Pfizer/BioNTech for their RNA-based Covid-19 vaccine. (c) AGC Biologics

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis